Skip to main content

Table 5 Multivariable Cox regression analysis of all-cause death in patients with atrial fibrillation, eGFR as a category variable

From: Impact of estimated glomerular filtration rate on long-term clinical outcomes among Chinese patients with atrial fibrillation

Variable HR represents HR (95%CI) P value
Total population    
 Age Per 1-year increment 1.018 (0.999–1.038) 0.063
 Male Versus female 2.441 (1.475–4.040) 0.001
 Duration of AF     < 0.001
  Persistent Versus paroxysmal 0.747 (0.347–1.608) 0.455
  Permanent Versus paroxysmal 2.187 (1.095–4.370) 0.027
 Warfarin Yes versus no 1.329 (0.753–2.348) 0.326
 TiTR  ≥ 66% versus < 66% 0.420 (0.122–1.443) 0.168
 eGFR    0.001
 60–89 ml/(min·1.73 m2) Versus ≥ 90 ml/(min·1.73 m2) 1.304 (0.618–2.750) 0.485
  < 60 ml/(min·1.73 m2) Versus ≥ 90 ml/(min·1.73 m2) 2.969 (1.447–6.093) 0.003
Individuals with EHRA Type 1 VHDs    
 Age Per 1-year increment 1.044 (0.996–1.095) 0.074
 Male Versus female 1.912 (0.692–5.284) 0.212
 Duration of AF    0.367
  Persistent Versus paroxysmal 2.006 (0.202–19.970) 0.553
  Permanent Versus paroxysmal 3.525 (0.450–27.638) 0.231
 TiTR  ≥ 66% versus < 66% 0.452 (0.112–1.823) 0.264
 Warfarin Yes versus no 0.932 (0.326–2.660) 0.895
 eGFR    0.339
 60–89 ml/(min·1.73 m2) Versus ≥ 90 ml/(min·1.73 m2) 1.264 (0.316–5.049) 0.740
  < 60 ml/(min·1.73 m2) Versus ≥ 90 ml/(min·1.73 m2) 2.522 (0.587–10.843) 0.214
Individuals with EHRA Type 2 VHDs    
 Age Per 1-year increment 1.075 (1.004–1.151) 0.038
 Male Versus female 2.806 (0.640–12.315) 0.171
Duration of AF    0.173
 Persistent Versus paroxysmal 13.838 (0.877–218.340) 0.062
 Permanent Versus paroxysmal 3.615 (0.583–22.423) 0.167
 CHA2DS2-VASc score Per 1 score increment 0.619 (0.328–1.168) 0.138
 Warfarin Yes versus no 2.447 (0.516–11.603) 0.260
eGFR    0.187
 60–89 ml/(min·1.73 m2) Versus ≥ 90 ml/(min·1.73 m2) 0.517 (0.036–7.409) 0.517
 < 60 ml/(min·1.73 m2) Versus ≥ 90 ml/(min·1.73 m2) 2.265 (0.217–23.591) 0.494
Individuals without VHDs    
 Age Per 1-year increment 0.993 (0.963–1.023) 0.641
 Male Versus female 3.593 (1.684–7.667) 0.001
 Duration of AF    0.003
  Persistent Versus paroxysmal 0.586 (0.234–1.465) 0.253
  Permanent Versus paroxysmal 1.921 (0.784–4.707) 0.153
 CHA2DS2-VASc score Per 1 score increment 1.121 (0.915–1.374) 0.271
 Warfarin Yes versus no 1.307 (0.542–3.151) 0.550
 eGFR    0.007
 60–89 ml/(min·1.73 m2) Versus ≥ 90 ml/(min·1.73 m2) 1.433 (0.546–3.763) 0.465
  < 60 ml/(min·1.73 m2) Versus ≥ 90 ml/(min·1.73 m2) 3.660 (1.402–9.556) 0.008
  1. Models were adjusted by age, sex (male vs female), duration of AF, use of warfarin, TiTR (if available), CHADS-VASc score (if available) and eGFR. VHDs indicates valvular heart diseases
  2. CHA2DS2-VASc score was calculated by Congestive heart failure, Hypertension, Age ≥ 75 years (doubled), Diabetes mellitus, Prior Stroke or TIA (doubled), Vascular disease, Age 65 to74 years, female Sex. AF indicates atrial fibrillation
  3. TiTR time in therapeutic range, CI confidential interval, HR hazard ratio, eGFR estimated Glomerular filtration rate